Global Information
회사소개 | 문의 | 비교리스트

약물 남용 억제제 : 파이프라인 분석

Abuse Deterrents - Pipeline Analytics, H1 2019

리서치사 GervanoRA Data Services LLP
발행일 2019년 03월 상품 코드 813723
페이지 정보 영문 188 Pages
가격
US $ 2,500 ₩ 3,098,000 PDF by E-mail (General License)


약물 남용 억제제 : 파이프라인 분석 Abuse Deterrents - Pipeline Analytics, H1 2019
발행일 : 2019년 03월 페이지 정보 : 영문 188 Pages

세계의 약물 중독·남용 억제제(Abuse Deterrents) 시장을 분석했으며, 미충족 요구 및 시장 기회, 전체적인 시장 동향의 실적·예측, 임상시험의 진전 상황, 제품 카테고리별 상세 동향, 주요 기업의 개요와 SWOT 분석, 현재 임상시험중인 제품과 향후 전망, 임상시험에 참가하고 있는 기업·대학·연구기관의 리스트 등의 정보를 정리하여 전해드립니다.

제1장 서론

제2장 개요

제3장 각성제 중독(코카인, 메스암페타민) 시장 개요

  • 각성제 중독의 개요
  • 세계 시장 시나리오
  • 각성제 중독 역학
  • 역학적 예측
  • 각성제 중독 : 제안되고 있는 치료법

제4장 각성제 남용의 개요

  • 각성제의 남용과 억제
  • 각성제 남용의 촉진요인
  • 각성제 남용의 영향과 증상
  • 각성제 남용의 현재 치료법
  • 각성제 남용 : 건강·사회·경제에 대한 영향

제5장 남용 억제제 시장의 자본거래 개요

  • 자본거래 동향(기업인수합병(M&A), 협업)
    • 협업 협정
    • 라이선스 협정
    • 시중 계약·조정
    • 자금 융자·계약
    • 사업 제휴
    • 기업 인수

제6장 각성제 남용 억제제 시장 : 최근 동향과 기술

  • 각성제 남용 억제제의 처방 전략
  • 각성제 남용 억제제의 처방 기술
  • 남용 물질의 국제기준
  • 각성제 남용의 치료에 관한 의료상 미충족 요구와 갭
  • 각성제 남용 : 세계 동향과 규제 정비
  • 각성제 남용 억제제 : 처방상 제한

제7장 코카인·메스암페타민 남용 억제제 : 파이프라인 분석

  • 임상시험중인 치료제 : 단계별
    • 제II상 분자
    • 제I상 분자
    • 전임상 단계 분자
    • 조기 R&D 단계 분자
    • 불활성 분자
  • 파이프라인 분석 : 지역별
  • 파이프라인 분석 : 투여 경로별
  • 파이프라인 분석 : 대학·기업·연구기관별

제8장 각성제 남용 억제제의 파이프라인 분석

  • 파이프라인 분석 : 임상시험 단계별
    • 승인전 분자
    • 제III상 분자
    • 제II상 분자
    • 제I상 분자
    • 전임상 분자
    • 조기 R&D(DISCOVERY) 단계 분자
  • 파이프라인 분석 : 지역별
  • 파이프라인 분석 : 투여 경로별
  • 파이프라인 분석 : 약제 클래스별
  • 파이프라인 분석 : 작용기서별
  • 파이프라인 분석 : 대학·기업·연구기관별

제9장 상정 약제 승인 타임라인

  • 분석 방법
  • 각성제 남용 억제제의 출시 시기 분석
  • 코카인·메스암페타민 남용 억제제의 출시 시기 분석
    • 미국의 경우(FDA)
    • 유럽의 경우(EMA/국제기관)

제10장 임상시험 개요

  • 코카인·메스암페타민 남용 억제제
    • 파이프라인 분석 : 임상시험 성과별
    • 현재 진행중인 임상시험 : 개요
    • 계획중인 임상시험 : 개요
    • 최근 완료된 임상시험
  • 각성제 남용 억제제
    • 파이프라인 분석 : 임상시험 성과별
    • 계획중인 임상시험 : 개요
    • 최근 완료된 임상시험
  • 중지된 프로젝트

제11장 현재·향후 경쟁 환경

  • 신규 참여 기업
  • 신규 진출 기업의 개요와 약제 개요 및 마일스톤
    • 코카인·메스암페타민 남용 억제제의 경우
    • 각성제 남용 억제제의 경우
  • 대학·연구기관

제12장 약어 리스트

KSA 19.04.09

GervanoRA's pipeline analysis and opportunity assessment report "Abuse Deterrents: Pipeline Analytics, H1 2019" analyzed and assessed the pipeline molecules for Abuse Deterrents along with Stimulant Addiction (Cocaine and Methamphetamine) Market Overview by considering the global scenarios, epidemiology and proposed treatments for the Stimulant Addiction. The report also provides information related to Stimulant Abuse and Deterrence, factors affecting, treatments and impact on Health, Social and Economy through Stimulant Abuse. The Report also focuses on the global trends, recent developments and technologies like the formulation strategies and formulation technologies. For a good understanding about the report we have provided the Pipeline Analysis for Abuse Deterrents based on two segments- Cocaine and Methamphetamine Drug Abuse Deterrent and Stimulant Drug Abuse Deterrent. We have in turn segmented the Chapter with respect to the Highest Stage of development, Geography, Route of Administration, Drug Class and Mechanism of Action.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORTS MAJOR FINDINGS
  • 2.2. KEY PIPELINE EVENTS 2018 TO 2034

3. STIMULANT ADDICTION (COCAINE & METHAMPHETAMINE) MARKET OVERVIEW

  • 3.1. STIMULANT ADDICTION OVERVIEW
  • 3.2. STIMULANT ADDICTION GLOBAL SCENARIOS
  • 3.3. STIMULANT ADDICTION EPIDEMIOLOGY
  • 3.4. EPIDEMIOLOGY FORECAST
    • 3.4.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.4.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
  • 3.5. STIMULANT ADDICTION PROPOSED TREATMENTS

4. STIMULANT ABUSE OVERVIEW

  • 4.1. STIMULANT ABUSE AND DETERRENCE
  • 4.2. FACTORS AFFECTING ON STIMULANT ABUSE
  • 4.3. EFFECTS AND SYMPTOMS OF STIMULANT ABUSE
  • 4.4. CURRENT TREATMENTS OF STIMULANT ABUSE
  • 4.5. STIMULANT ABUSE - IMPACT ON HEALTH, SOCIAL AND ECONOMY

5. ABUSE DETERRENT DEALS OVERVIEW

  • 5.1. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    • 5.1.1. COLLABORATION AGREEMENTS
    • 5.1.2. LICENSING AGREEMENTS
    • 5.1.3. TERMINATION AGREEMENTS AND SETTLEMENTS
    • 5.1.4. FUNDING & CONTRACTS
    • 5.1.5. PARTNERSHIPS
    • 5.1.6. ACQUISITIONS

6. STIMULANT ABUSE DETERRENTS-RECENT DEVELOPMENTS AND TECHNOLOGIES

  • 6.1. STIMULANT ABUSE DETERRENT FORMULATION STRATEGIES
  • 6.2. STIMULANT ABUSE DETERRENT FORMULATION TECHNOLOGIES
  • 6.3. INTERNATIONAL GUIDELINES FOR ABUSABLE SUBSTANCES
  • 6.4. UNMET MEDICAL NEEDS AND GAPS IN THE TREATMENT OF STIMULANT ABUSE
  • 6.5. STIMULANT ABUSE GLOBAL TRENDS AND REGULATORY DEVELOPMENTS
  • 6.6. LIMITATIONS OF STIMULANT ABUSE DETERRENT FORMULATIONS

7. PIPELINE ANALYSIS OF COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT

  • 7.1. THERAPEUTICS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT
    • 7.1.1. PHASE II MOLECULES
    • 7.1.2. PHASE I MOLECULES
    • 7.1.3. PRECLINICAL MOLECULES
    • 7.1.4. EARLY R&D MOLECULES
    • 7.1.5. INACTIVE MOLECULES
  • 7.2. PIPELINE ANALYSIS BY GEOGRAPHY
  • 7.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • 7.4. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES

8. PIPELINE ANALYSIS OF STIMULANT DRUG ABUSE DETERRENT

  • 8.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 8.1.1. PRE-REGISTRATION (FILED) MOLECULES
    • 8.1.2. PHASE III MOLECULES
    • 8.1.3. PHASE II MOLECULES
    • 8.1.4. PHASE I MOLECULES
    • 8.1.5. PRECLINICAL MOLECULES
    • 8.1.6. EARLY R&D (DISCOVERY) MOLECULES
  • 8.2. PIPELINE ANALYSIS BY GEOGRAPHY
  • 8.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • 8.4. PIPELINE ANALYSIS BY DRUG CLASS
  • 8.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
  • 8.6. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES

9. ESTIMATED DRUG APPROVAL TIMELINES

  • 9.1. METHODOLOGY
  • 9.2. STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS
    • 9.2.1. UNITED STATES (FDA) ESTIMATIONS
    • 9.2.2. EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS
  • 9.3. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS
    • 9.3.1. UNITED STATES (FDA) ESTIMATIONS
    • 9.3.2. EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS

10. CLINICAL TRIAL SUMMARY

  • 10.1. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT
    • 10.1.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    • 10.1.2. ONGOING CLINICAL TRIALS SUMMARY
    • 10.1.3. PLANNED CLINICAL TRIAL SUMMARY
    • 10.1.4. RECENTLY COMPLETED CLINICAL TRIALS
  • 10.2. STIMULANT DRUG ABUSE DETERRENT
    • 10.2.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    • 10.2.2. PLANNED CLINICAL TRIAL SUMMARY
    • 10.2.3. RECENTLY COMPLETED TRIALS
  • 10.3. WITHDRAWN AND DISCONTINUED PROJECTS

11. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 11.1. EMERGING COMPANIES
  • 11.2. EMERGING COMPANY PROFILES WITH DRUG DESCRIPTIONS AND MILESTONES
    • 11.2.1. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT EMERGING COMPANIES
    • 11.2.2. STIMULANT DRUG ABUSE DETERRENT EMERGING COMPANIES
  • 11.3. UNIVERSITIES AND INSTITUTES

12. ABBREVIATIONS

LIST OF TABLES

  • TABLE 1: METHAMPHETAMINE V/S COCAINE
  • TABLE 2: ILLICIT DRUG USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 3: STIMULANT USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 4: COCAINE USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 5: METHAMPHETAMINE USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 6: COLLABORATION AGREEMENTS, 2000-2018
  • TABLE 7: LICENSING AGREEMENTS, 2013-2018
  • TABLE 8: TERMINATION AGREEMENTS
  • TABLE 9: FUNDING AND CONTRACTS
  • TABLE 10: PARTNERSHIPS DEALS
  • TABLE 11: ACQUISITION DEALS
  • TABLE 12: STAGE OF DEVELOPMENT V/S FORMULATION STRATEGIES
  • TABLE 13: MOLECULES BELONGING TO TYPE 3 FORMULATION STRATEGY
  • TABLE 14: MOLECULES BELONGING TO TYPE 2 FORMULATION STRATEGY
  • TABLE 15: MOLECULE BELONGING TO TYPE 1 FORMULATION STRATEGY
  • TABLE 16: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PHASE II PIPELINE MOLECULES
  • TABLE 17: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PHASE I PIPELINE MOLECULES
  • TABLE 18: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PRECLINICAL STAGE PIPELINE MOLECULES
  • TABLE 19: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT EARLY R&D PIPELINE MOLECULES
  • TABLE 20: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT INACTIVE PIPELINE MOLECULES
  • TABLE 21: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • TABLE 22: PRE-REGISTRATION (FILED) MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 23: PHASE III MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 24: PHASE II MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 25: PHASE I MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 26: PRECLINICAL MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 27: EARLY R&D MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 28: LIST OF COMPANIES WITH PIPELINE MOLECULES BY STAGE OF DEVELOPMENT
  • TABLE 29: LIST OF UNIVERSITIES AND INSTITUTES WITH PIPELINE MOLECULES
  • TABLE 30: STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS, US APPROVAL
  • TABLE 31: STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS, EX US APPROVAL
  • TABLE 32: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS, US APPROVAL
  • TABLE 33: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS, EX US APPROVAL
  • TABLE 34: MN-166 (IBUDILAST) PHASE II CLINICAL TRIAL STUDY DESIGN
  • TABLE 35: SYN117 (NEPICASTAT) PHASE II CLINICAL TRIAL STUDY DESIGN
  • TABLE 36: MEASURED VALUE FOR PRIMARY MEASURE- ABSTINENCE
  • TABLE 37: MEASURED VALUE FOR SECONDARY MEASURE- REDUCTION IN USE
  • TABLE 38: ONGOING PHASE II CLINICAL TRIALS
  • TABLE 39: ORADUR-METHYLPHENIDATE ER PHASE III CLINICAL TRIALS STUDY DESIGN
  • TABLE 40: HLD200 PHASE III CLINICAL TRIALS STUDY DESIGN
  • TABLE 41: HLD200 SECOND PIVOTAL PHASE III CLINICAL TRIALS STUDY DESIGN
  • TABLE 42: HLD100 PHASE II TRIAL RESULTS
  • TABLE 43: RBP-8000 PHASE II CLINICAL TRIALS STUDY DESIGN
  • TABLE 44: LIST OF UNIVERSITIES AND INSTITUTES

LIST OF FIGURES

  • FIGURE 1: KEY PIPELINE EVENTS, COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT, 2021-2023
  • FIGURE 2: KEY PIPELINE EVENTS, COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT, 2024-2028
  • FIGURE 3: KEY PIPELINE EVENTS, STIMULANT DRUG ABUSE DETERRENT, 2018-2034
  • FIGURE 4: COCAINE USE TRENDS, US, 2002-2016
  • FIGURE 5: COCAINE USE TRENDS, CANADA, 2004-2009
  • FIGURE 6: RELATIVE COMPARISION IN PREVALENCE OF COCAINE AND METHAMPHETAMINE DRUG USE, 2009-2013
  • FIGURE 7: COMPARISION OF COCAINE USERS BY AGE GROUP, 2015-2016
  • FIGURE 8: COMPARISION OF METHAMPHETAMINE USERS BY AGE GROUP, 2015-2016
  • FIGURE 9: COCAINE USE, 2015-2016
  • FIGURE 10: ILLICIT DRUG USERS, US, 2010-2016
  • FIGURE 11: PREVALENCE OF COCAINE USE, AGE GROUP, CANADA, 2008-2015
  • FIGURE 12: ILLICIT DRUG USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 13: STIMULANT USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 14: COCAINE USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 15: METHAMPHETAMINE USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 16: PHARMACOLOGICAL TREATMENT OPTIONS FOR STIMULANT ADDICTION
  • FIGURE 17: DEAL ACTIVITY, CNS STIMULANTS AND OPIOIDS
  • FIGURE 18: STRATEGIES FOR STIMULANT ABUSE DETERRENT FORMULATION
  • FIGURE 19: ANNUAL PREVALENCE AND NUMBER OF ILLICIT DRUG USERS AT THE GLOBAL LEVEL, 2010
  • FIGURE 20: ILLICIT DRUG USE AT THE GLOBAL LEVEL, 2008
  • FIGURE 21: COMPARISION BETWEEN FEMALE AND MALE USERS ATTRIBUTABLE TO DRUG USE DISORDERS, 2005 AND 2015
  • FIGURE 22: DALY'S COMPARISION BETWEEN FEMALE AND MALE USERS ATTRIBUTABLE TO DRUG USE DISORDERS, 2005 AND 2015
  • FIGURE 23: ANNUAL PREVALENCE OF THE USE OF COCAINE AND METHAMPHETAMINE BY REGION AND GLOBALLY, 2015
  • FIGURE 24: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIGURE 25: STIMULANT DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT- COMPANIES
  • FIGURE 26: STIMULANT DRUG DETERRENT PIPELINE ANALYSIS BY GEOGRAPHY
Back to Top
전화 문의
F A Q